Skip to content
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Psychedelic Policy Reform & Legal Markets in 2023

Psychedelic Policy Reform & Legal Markets in 2023

  • Post published:January 30, 2024
  • Post category:2023 Year in Review/Analysis
Read more about the article Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development

Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development

  • Post published:January 25, 2024
  • Post category:Analysis/Opinions
Read more about the article European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients

European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients

  • Post published:January 24, 2024
  • Post category:Analysis/News
Read more about the article Psychedelics M&A and Partnerships in 2023

Psychedelics M&A and Partnerships in 2023

  • Post published:January 22, 2024
  • Post category:2023 Year in Review/Analysis
Read more about the article Psychedelic Funding & Public Markets in 2023

Psychedelic Funding & Public Markets in 2023

  • Post published:January 18, 2024
  • Post category:2023 Year in Review/Analysis
Read more about the article Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators

Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators

  • Post published:January 17, 2024
  • Post category:Analysis/Pα+
Read more about the article Reflecting on Psychedelics in 2023

Reflecting on Psychedelics in 2023

  • Post published:January 16, 2024
  • Post category:2023 Year in Review/Analysis
Read more about the article Our Top 10 Psychedelics Articles in 2023

Our Top 10 Psychedelics Articles in 2023

  • Post published:January 11, 2024
  • Post category:2023 Year in Review/Analysis
Read more about the article The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

  • Post published:January 9, 2024
  • Post category:Analysis/News
Read more about the article MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics

MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics

  • Post published:January 5, 2024
  • Post category:Analysis/News

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More